Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727817 | 1.00 | FOLH1 (0.53) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL1413149 | 1.00 | FOLH1 (0.53) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL7027613 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL3725106 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL7027611 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL24764859 | 0.88 | FOLH1 (0.54) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL4951252 | 0.87 | GSR (0.52) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL1116199 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL5419504 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL23451044 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633656-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4633657-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Parabilis Medicines, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | claimed |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | claimed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-3548512-B1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | AXOLTIS PHARMA (FR) | 2023-08-02 | — | — | EP | claimed |
| WO-2022261257-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-2427775-B1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN PEPTIDES SA (ES) | 2021-08-11 | — | — | EP | claimed |
| EP-0540676-B1 | PEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | POLYGEN HOLDING CORP (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0593491-A1 | LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST PEPTIDES. | DEGHENGHI ROMANO (CH) | 1994-04-27 | — | — | EP | claimed |
| EP-0434675-B1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | POLYGEN HOLDING CORPORATION (US) | 1993-09-01 | — | — | EP | claimed |
| WO-1992019651-A1 | LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST PEPTIDES | DEGHENGHI ROMANO (CH) | 1992-11-12 | — | — | WO | claimed |
| EP-0434675-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1991-07-03 | — | — | EP | claimed |
| EP-0417165-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400051-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989010933-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1989-11-16 | — | — | WO | claimed |
| WO-1989007110-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1989-08-10 | — | — | WO | claimed |
| WO-1988009780-A2 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1988-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | FOLH1 725/4885GSR 4268/4885RNPEP 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.